Use of fumaric acid derivatives for treating mitochondrial...

Details Use of fumaric acid derivatives for treating mitochondrial... Use of fumaric acid derivatives for treating mitochondrial...

2005-02-22

2005-02-22

Richter, Johann (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C562S598000, C514S557000, C514S559000, C514S578000

Reexamination Certificate

active

06858750

ABSTRACT:
The present invention relates to the use of individual fumaric acid derivatives or mixtures thereof for preparing a pharmaceutical composition for treating mitochondrial diseases, especially for treating Parkinson's syndrome, Alzheimer's disease, Chorea Huntington disease, retinopathia pigmentosa and mitochondrial encephalomyopathy. Preferably, the fumaric acid derivative(s) is/are those selected from the group consisting of fumaric acid dialkyl esters or fumaric acid monoalkyl esters in the form of the free acid or a salt thereof.

REFERENCES:
patent: 3832287 (1974-08-01), Gale et al.
patent: 4515974 (1985-05-01), Zecher et al.
patent: 4746668 (1988-05-01), Sato et al.
patent: 4851439 (1989-07-01), Speiser et al.
patent: 4959389 (1990-09-01), Speiser et al.
patent: 5149695 (1992-09-01), Speiser et al.
patent: 5214196 (1993-05-01), Blank
patent: 5242905 (1993-09-01), Blank
patent: 5359128 (1994-10-01), Blank
patent: 5424332 (1995-06-01), Speiser et al.
patent: 5451667 (1995-09-01), Speiser et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5548059 (1996-08-01), Bayley et al.
patent: 5589504 (1996-12-01), Dannenberg et al.
patent: 5965591 (1999-10-01), Kojima et al.
patent: 5972363 (1999-10-01), Clikeman et al.
patent: 6005116 (1999-12-01), Kojima et al.
patent: 6277882 (2001-08-01), Joshi et al.
patent: 6355676 (2002-03-01), Joshi et al.
patent: 6359003 (2002-03-01), Joshi et al.
patent: 6436992 (2002-08-01), Joshi et al.
patent: 6509376 (2003-01-01), Joshi et al.
patent: 20020091087 (2002-07-01), Zhang et al.
patent: 20030013761 (2003-01-01), Joshi et al.
patent: 2248955 (2001-08-01), None
patent: 25 30 372 (1977-01-01), None
patent: 26 21 214 (1977-11-01), None
patent: 38 34794 (1990-04-01), None
patent: 0 188 749 (1986-07-01), None
patent: 0 312 697 (1989-04-01), None
patent: 2132187 (1999-06-01), None
patent: 2136291 (1999-09-01), None
patent: 2160589 (2000-12-01), None
patent: 5189813 (2002-09-01), None
patent: WO 8901930 (1989-03-01), None
patent: WO 9428883 (1994-12-01), None
patent: WO 9525102 (1995-09-01), None
patent: WO 9602244 (1996-02-01), None
patent: WO 9627369 (1996-09-01), None
patent: WO 9713504 (1997-04-01), None
patent: WO 9748400 (1997-12-01), None
patent: WO 9748405 (1997-12-01), None
patent: WO 9804290 (1998-02-01), None
patent: WO 9827970 (1998-07-01), None
patent: WO 9852549 (1998-11-01), None
patent: WO 9921565 (1999-05-01), None
Douglas C. Wallace, Science, vol. 283, Mar. 5, 1999.*
Amamoto, Toshiro, et al., “Effect of E-64, Thiol Protease Inhibitor on the Secondary Anti-SRBC Response In Vitro”, Microbiol. Immunol., vol. 28(1), 1984, ppg 85-97.
Barrett, Alan J., et al., “L-trans-Epoxysuccinyl-leucylamido(4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L”, Biochem. J., 1982, vol. 201, ppg 189-198.
Bellier, Bruno, et al., “Replacement of Glycine with Dicarbonyl and Related Moieties in Analogues of the C-Terminal Pentapeptide of Cholecystokinin: CCK2Agonists Displaying a Novel Binding Mode”, J. Med. Chem., vol. 43, 2000, ppg 3614-3623.
Birch, A.J., et al., “Metabolites ofAspergillus indicus:The Structure and Some Aspects of the Biosynthesis of Dihydrocanadensolide”, Aust. J. Chem., 1968, vol. 21, ppg 2775-2784.
Choo, Hea-Young, et al., “Design and Synthesis of α,β-unsaturated Carbonyl Compounds as Potential ACE Inhibitors”, Short Communication, Eur. J. Med. Chem., vol. 35, 2000, ppg 643-648.
Dethlefsen, L.A., “Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells”, Radiation Research, vol. 114, 1988, ppg 215-224.
Galpin, I.J., et al., “The Synthesis of an Insulin Active Site Analogue”, Tetrahedron, vol. 39, No. 1, 1983, ppg 149-158.
Gerhard, Ute, et al., “The Free Energy Change of restricting A Bond Rotation in the Binding of Peptide Analogues to Vancomycin Group Antibiotics”, Bioorganic & Medicinal Chemistry Letters, vol. 3, No. 5, 1993, ppg 803-808.
Gordon, G.B., et al., “Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes”, Carcinogenesis, vol. 12 (12), 1991, ppg 2393-2396.
Griehl, C., et al., “α-Aspartyl Peptides by Addition of Amines to N-Maleylamino Acid Derivatives”, Chemistry of Peptides and Proteins, 1993, 5/6(pt. A), pp 99-103.
Hildebrandt, H., “Pschyrembel Klinisches Woerterbuch Ed. 258”, Walter de Gruyter, New York, XP 002234302, p. 182, column 1, paragraph 2 and p. 1469, column 1, paragraph 16-column 2, paragraph 1. Not translated.
Hohenegger, M., et al., “Nephrotoxicity of Fumaric Acid Monoethylester (FA ME)”, Advances in Experimental Medicine and Biology, US 1989, vol. 252, ppg 265-272.
Holroyd, S.E., et al., “Rational Design and Binding of Modified Cell-Wall Peptides to Vancomycin-Group Antibiotics: Factorising Free Energy Contributions to Binding”, Tetrahedron, vol. 49, No. 41, 1993, ppg 9171-9182.
Kamiyama, T., et al., “Ro 09-1679, A Novel Thrombin Inhibitor”, The Journal of Antibiotics, vol. 45, No. 3, Mar. 1992, ppg 424-427.
Krstenansky, J.L., et al., “Development of MDL 28,050, a Small Stable Antithrombin Agent Based on a Functional Domain of the Leech Protein, Hirudin”, Thrombosis and Haemostasis, vol. 63, No. 2, 1990, Stuttgart, De.
Kuroda, K., et al., “Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counter Acting the Toxicities of Mitomycin C and Aflatoxin B1”, Jpn. J. Cancer Res. (Gann), Aug. 1986, vol. 77, ppg 750-758.
Kuroda, K., et al., “Inhibitory Effect ofCapsella-bursa-pastorisextract on Growth of Ehrlich Solid Tumor in Mice”, Cancer Research, vol. 36, 1976, Abstract only.
Langlois, M., et al., “Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-1 protease”, Eur. J. Med. Chem., vol. 29, 1994, ppg 639-647.
Lehnert, S., et al., “Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion”, Radiation Research, vol. 124, 1990, ppg 208-215.
Miller, A.C., et al., “Posttranscriptional Down-Regulation of ras Oncogene Expression by Inhibitors of Cellular Glutathione”, Molecular and Cellular Biology, Jul. 1993, vol. 13, No. 7, ppg 4416-4422.
Mrowietz, U., “Nephrotoxische Wirkung durch Fumarsaure”, Hautarzt, 2000-51:615, Springer-Verlag 2000, p. 615. Not translated.
Odom, R. Y., et al., “Cancer Chemoprotective Agents Inhibition of Human HT29 Colon Carcinoma Cell Proliferation is Reversed by N-Acetyl Cysteine”, Proceedings of the American Assoc. for Cancer Research Annual, No. 41, Mar. 2000, p. 342, XP008017517.
Ondrus, V., et al., “A Simple Synthesis of Some analogues of Natural Antibiotics”, Preliminary Communication, Chem. Papers, 51(3), 1997, ppg 164-166.
Orta, T., et al., “Glutathione manipulation and the radiosensitivity of human tumour and fibroblast cell lines”, Int. J. Radiat. Biol., 1995, vol. 68, No. 4, ppg 413-419.
Pearl, J.M., et al., “Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium”, Annals of Thoracic Surgery, vol. 57, No. 6, 1994, Abstract only, 1 page.
Peeters, A.J., et al., “Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study”, British Journal of Rheumatology, vol. XXXI, No. 7, Jul. 1992, ppg 502-504.
Pereira, M.A., et al., “Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents”, Carcinogenesis, vol. 15, No. 5, 1994, ppg 1049-1054.
Portoghese, P.S., et al., “Synthesis and Biological Activity of Analogues of β-Chlornaltrexamine and β-Funaltrexamine at Opioid Receptors”, J. of Medicinal Chem., vol. 29, No. 10, 1986, ppg 1861-1864.
Prochaska, H.J., et al., 

Affiliated with

Also associated with

Rating

Use of fumaric acid derivatives for treating mitochondrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of fumaric acid derivatives for treating mitochondrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of fumaric acid derivatives for treating mitochondrial... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3444516